Sarepta Therapeutics (SRPT) Receives New Coverage from Analysts at HC Wainwright

Equities researchers at HC Wainwright assumed coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a note issued to investors on Friday. The firm set a “buy” rating and a $75.00 price target on the biotechnology company’s stock. HC Wainwright’s target price would indicate a potential upside of 34.72% from the company’s current price.

Other analysts have also recently issued research reports about the company. SunTrust Banks reaffirmed a “buy” rating and set a $56.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, September 7th. Oppenheimer reissued a “buy” rating and issued a $76.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, September 7th. Needham & Company LLC reiterated a “buy” rating and issued a $75.00 target price on shares of Sarepta Therapeutics in a report on Wednesday, September 6th. Nomura reissued a “buy” rating and issued a $84.00 price objective on shares of Sarepta Therapeutics in a report on Tuesday, September 5th. Finally, Instinet reaffirmed a “buy” rating and set a $84.00 price target on shares of Sarepta Therapeutics in a report on Monday, October 2nd. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and seventeen have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $64.14.

Shares of Sarepta Therapeutics (NASDAQ SRPT) opened at $55.67 on Friday. Sarepta Therapeutics has a one year low of $26.26 and a one year high of $57.57. The company has a debt-to-equity ratio of 0.04, a current ratio of 10.44 and a quick ratio of 9.52.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Wednesday, October 25th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.86) by $0.66. The business had revenue of $45.95 million for the quarter, compared to analyst estimates of $41.29 million. Sarepta Therapeutics had a negative net margin of 112.08% and a negative return on equity of 51.72%. During the same quarter in the previous year, the business earned ($0.95) earnings per share. equities research analysts forecast that Sarepta Therapeutics will post -3.11 earnings per share for the current year.

In related news, SVP Shamim Ruff sold 11,500 shares of the firm’s stock in a transaction that occurred on Tuesday, October 3rd. The stock was sold at an average price of $50.00, for a total transaction of $575,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Douglas S. Ingram acquired 38,138 shares of Sarepta Therapeutics stock in a transaction on Wednesday, November 8th. The shares were purchased at an average price of $52.44 per share, for a total transaction of $1,999,956.72. Following the completion of the acquisition, the chief executive officer now directly owns 420,196 shares in the company, valued at $22,035,078.24. The disclosure for this purchase can be found here. Company insiders own 9.60% of the company’s stock.

A number of large investors have recently bought and sold shares of SRPT. J. Goldman & Company purchased a new position in Sarepta Therapeutics in the third quarter valued at $58,000. Teacher Retirement System of Texas grew its holdings in shares of Sarepta Therapeutics by 13.6% during the second quarter. Teacher Retirement System of Texas now owns 6,034 shares of the biotechnology company’s stock worth $115,000 after purchasing an additional 724 shares during the last quarter. Prentiss Smith & Co. Inc. grew its holdings in shares of Sarepta Therapeutics by 772.2% during the second quarter. Prentiss Smith & Co. Inc. now owns 3,576 shares of the biotechnology company’s stock worth $121,000 after purchasing an additional 3,166 shares during the last quarter. Ameritas Investment Partners Inc. purchased a new position in shares of Sarepta Therapeutics during the first quarter worth about $127,000. Finally, PNC Financial Services Group Inc. grew its holdings in shares of Sarepta Therapeutics by 150.1% during the first quarter. PNC Financial Services Group Inc. now owns 4,666 shares of the biotechnology company’s stock worth $138,000 after purchasing an additional 2,800 shares during the last quarter. Institutional investors own 82.02% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was first published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another publication, it was illegally stolen and republished in violation of U.S. & international copyright law. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/12/01/sarepta-therapeutics-srpt-receives-new-coverage-from-analysts-at-hc-wainwright.html.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply